6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine profile

ID Source	ID
PubMed CID	44142051
CHEMBL ID	1394132
CHEBI ID	92861

Synonym
NCGC00183226-01
smr001318030
MLS002276492
CHEMBL1394132 ,
6-(1-methyl-1h-indol-5-yl)-n-(thiophen-2-ylmethyl)quinazolin-4-amine
bdbm50342924
HMS2228D08
HMS3329F05
CHEBI:92861
Q27164613
6-(1-methyl-5-indolyl)-n-(thiophen-2-ylmethyl)-4-quinazolinamine

Class	Description
quinazolines	Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	28.1838	0.6310	35.7641	100.0000	AID504339
Luciferase	Photinus pyralis (common eastern firefly)	Potency	30.1313	0.0072	15.7588	89.3584	AID588342
chaperonin-containing TCP-1 beta subunit homolog	Homo sapiens (human)	Potency	107.5085	3.9811	27.7649	39.8107	AID504842
ATAD5 protein, partial	Homo sapiens (human)	Potency	5.8024	0.0041	10.8903	31.5287	AID504467
Smad3	Homo sapiens (human)	Potency	25.1189	0.0052	7.8098	29.0929	AID588855
PINK1	Homo sapiens (human)	Potency	44.6684	2.8184	18.8959	44.6684	AID624263
Parkin	Homo sapiens (human)	Potency	44.6684	0.8199	14.8306	44.6684	AID624263
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	89.1251	0.7079	36.9043	89.1251	AID504333
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	29.0929	0.0041	9.9848	25.9290	AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	35.4813	3.5481	19.5427	44.6684	AID743266
dual specificity tyrosine-phosphorylation-regulated kinase 1A isoform 1	Homo sapiens (human)	Potency	46.2666	0.0130	7.4878	29.1922	AID2705
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	7.9433	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	16.0892	0.0046	11.3741	33.4983	AID624296; AID624297
dual specificity protein kinase CLK4	Homo sapiens (human)	Potency	24.6440	0.0116	3.7867	31.6228	AID1969; AID1970; AID1983
Adenosine receptor A1	Rattus norvegicus (Norway rat)	Potency	14.1254	0.0631	4.1371	15.8489	AID1969
Adenosine receptor A3	Rattus norvegicus (Norway rat)	Potency	14.1254	0.0631	3.8038	14.1254	AID1969
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	Potency	14.1254	0.0631	3.8038	14.1254	AID1969
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	Potency	14.1254	0.0631	3.8038	14.1254	AID1969
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	IC50 (µMol)	4.5170	0.0031	0.7140	9.0120	AID594049
Dual specificity protein kinase CLK4	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0110	1.0694	7.9430	AID594050
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
chromatin remodeling	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nervous system development	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
circadian rhythm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of microtubule polymerization	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of RNA splicing	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
amyloid-beta formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of mRNA splicing, via spliceosome	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of protein deacetylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
regulation of RNA splicing	Dual specificity protein kinase CLK4	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity protein kinase CLK4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
identical protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau-protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
histone H3T45 kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
transcription coactivator activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein binding	Dual specificity protein kinase CLK4	Homo sapiens (human)
ATP binding	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
cytoskeleton	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nuclear speck	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
axon	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
dendrite	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ribonucleoprotein complex	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID594049	Inhibition of Dyrk1A kinase using ATP as substrate by 33P radiolabeled kinase assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
AID594050	Inhibition of Clk4 kinase using ATP as substrate by 33P radiolabeled kinase assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes
tg 003 TG 003: a Clk inhibitor; structure in first source	2.06	1
ml106 ML106: imidazobenzimidazole, inhibits melanin synthesis; structure in first source	2.06	1	quinazolines
6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine [no description available]	2.06	1	quinazolines
[5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol [no description available]	2.06	1	quinazolines

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine

Cross-References

Synonyms (11)

Drug Classes (1)

Protein Targets (22)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (15)

Ceullar Components (9)

Bioassays (15)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine

Cross-References

Synonyms (11)

Drug Classes (1)

Protein Targets (22)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (15)

Ceullar Components (9)

Bioassays (15)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.35

Study Types

Related Drugs (12)

Related Conditions (2)